A detailed history of Creative Planning transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Creative Planning holds 11,793 shares of REGN stock, worth $8.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,793
Previous 9,615 22.65%
Holding current value
$8.93 Million
Previous $10.1 Million 22.68%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$1024.09 - $1201.76 $2.23 Million - $2.62 Million
2,178 Added 22.65%
11,793 $12.4 Million
Q2 2024

Aug 15, 2024

BUY
$883.2 - $1071.19 $875,251 - $1.06 Million
991 Added 11.49%
9,615 $10.1 Million
Q1 2024

May 10, 2024

BUY
$902.69 - $993.35 $1.39 Million - $1.52 Million
1,535 Added 21.65%
8,624 $8.3 Million
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $326,350 - $371,195
421 Added 6.31%
7,089 $6.23 Million
Q3 2023

Nov 16, 2023

BUY
$692.45 - $844.37 $381,539 - $465,247
551 Added 9.01%
6,668 $5.49 Million
Q2 2023

Jul 21, 2023

BUY
$700.03 - $830.35 $245,010 - $290,622
350 Added 6.07%
6,117 $4.4 Million
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $438,916 - $533,395
645 Added 12.59%
5,767 $4.74 Million
Q4 2022

Feb 10, 2023

BUY
$705.89 - $766.39 $516,005 - $560,231
731 Added 16.65%
5,122 $3.7 Million
Q3 2022

Nov 03, 2022

BUY
$573.97 - $724.32 $268,043 - $338,257
467 Added 11.9%
4,391 $3.03 Million
Q2 2022

Aug 15, 2022

BUY
$548.35 - $738.84 $671,728 - $905,079
1,225 Added 45.39%
3,924 $2.32 Million
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $14,878 - $17,460
-25 Reduced 0.92%
2,699 $1.89 Million
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $146,739 - $181,161
270 Added 11.0%
2,724 $1.72 Million
Q3 2021

Nov 10, 2021

SELL
$574.03 - $680.96 $307,106 - $364,313
-535 Reduced 17.9%
2,454 $1.49 Million
Q2 2021

Aug 04, 2021

SELL
$472.8 - $558.54 $1.57 Million - $1.85 Million
-3,317 Reduced 52.6%
2,989 $1.67 Million
Q1 2021

Apr 30, 2021

BUY
$446.73 - $548.2 $625,868 - $768,028
1,401 Added 28.56%
6,306 $2.98 Million
Q4 2020

Jan 29, 2021

BUY
$478.3 - $607.98 $282,675 - $359,316
591 Added 13.7%
4,905 $2.37 Million
Q3 2020

Nov 05, 2020

BUY
$544.75 - $658.21 $329,573 - $398,217
605 Added 16.31%
4,314 $2.42 Million
Q2 2020

Jul 23, 2020

SELL
$493.32 - $643.92 $213,607 - $278,817
-433 Reduced 10.45%
3,709 $2.31 Million
Q1 2020

May 05, 2020

SELL
$336.18 - $494.43 $500,572 - $736,206
-1,489 Reduced 26.44%
4,142 $2.02 Million
Q4 2019

Jan 30, 2020

SELL
$274.13 - $376.51 $1.8 Million - $2.48 Million
-6,578 Reduced 53.88%
5,631 $2.11 Million
Q3 2019

Nov 01, 2019

BUY
$273.46 - $318.39 $54,965 - $63,996
201 Added 1.67%
12,209 $3.39 Million
Q2 2019

Jul 26, 2019

BUY
$299.6 - $414.82 $2.56 Million - $3.54 Million
8,529 Added 245.16%
12,008 $3.76 Million
Q1 2019

Apr 24, 2019

SELL
$372.08 - $439.57 $18,231 - $21,538
-49 Reduced 1.39%
3,479 $1.43 Million
Q4 2018

Feb 01, 2019

SELL
$335.82 - $403.04 $319,029 - $382,888
-950 Reduced 21.21%
3,528 $1.32 Million
Q3 2018

Oct 25, 2018

SELL
$351.14 - $408.51 $2.08 Million - $2.42 Million
-5,917 Reduced 56.92%
4,478 $1.81 Million
Q2 2018

Jul 20, 2018

BUY
$284.6 - $344.99 $352,334 - $427,097
1,238 Added 13.52%
10,395 $3.59 Million
Q1 2018

Apr 18, 2018

SELL
$315.82 - $393.78 $517,628 - $645,405
-1,639 Reduced 15.18%
9,157 $3.15 Million
Q4 2017

Jan 17, 2018

SELL
$358.63 - $469.95 $1.95 Million - $2.56 Million
-5,451 Reduced 33.55%
10,796 $4.06 Million
Q3 2017

Oct 17, 2017

BUY
$431.38 - $504.0 $7.01 Million - $8.19 Million
16,247
16,247 $7.26 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.